Jane Street Group LLC purchased a new position in Charles River Laboratories Intl. Inc (NYSE:CRL) during the 2nd quarter, HoldingsChannel reports. The firm purchased 5,284 shares of the medical research company’s stock, valued at approximately $593,000.

Several other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in Charles River Laboratories Intl. by 7.0% during the 2nd quarter. BlackRock Inc. now owns 4,446,965 shares of the medical research company’s stock valued at $499,216,000 after purchasing an additional 292,685 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Charles River Laboratories Intl. by 3.8% during the 2nd quarter. Renaissance Technologies LLC now owns 1,515,300 shares of the medical research company’s stock valued at $170,108,000 after purchasing an additional 55,000 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Charles River Laboratories Intl. by 5.4% during the 2nd quarter. Wells Fargo & Company MN now owns 1,316,635 shares of the medical research company’s stock valued at $147,806,000 after purchasing an additional 67,439 shares during the last quarter. Brown Advisory Inc. boosted its stake in Charles River Laboratories Intl. by 5.4% during the 2nd quarter. Brown Advisory Inc. now owns 702,500 shares of the medical research company’s stock valued at $78,863,000 after purchasing an additional 36,219 shares during the last quarter. Finally, Van Berkom & Associates Inc. boosted its stake in Charles River Laboratories Intl. by 0.7% during the 2nd quarter. Van Berkom & Associates Inc. now owns 617,391 shares of the medical research company’s stock valued at $69,308,000 after purchasing an additional 4,250 shares during the last quarter. Institutional investors own 97.78% of the company’s stock.

In other news, Director Deborah Turner Kochevar sold 4,066 shares of the firm’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $123.66, for a total value of $502,801.56. Following the transaction, the director now directly owns 10,190 shares in the company, valued at approximately $1,260,095.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Davide Molho sold 11,126 shares of the firm’s stock in a transaction on Tuesday, July 17th. The stock was sold at an average price of $120.00, for a total value of $1,335,120.00. Following the completion of the transaction, the chief operating officer now owns 44,805 shares in the company, valued at $5,376,600. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,019 shares of company stock worth $3,914,826. Company insiders own 2.10% of the company’s stock.

CRL has been the topic of several recent analyst reports. Argus increased their target price on Charles River Laboratories Intl. from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, August 27th. ValuEngine upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating in a research note on Tuesday, September 11th. Jefferies Financial Group increased their target price on Charles River Laboratories Intl. from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. SunTrust Banks increased their target price on Charles River Laboratories Intl. to $135.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, Bank of America increased their target price on Charles River Laboratories Intl. from $120.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, July 16th. Seven analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Charles River Laboratories Intl. currently has a consensus rating of “Buy” and a consensus price target of $128.50.

CRL stock opened at $122.99 on Friday. The firm has a market capitalization of $6.46 billion, a PE ratio of 23.34, a PEG ratio of 1.69 and a beta of 0.65. Charles River Laboratories Intl. Inc has a 1 year low of $96.70 and a 1 year high of $135.90. The company has a current ratio of 1.72, a quick ratio of 1.48 and a debt-to-equity ratio of 1.52.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 8th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.46 by $0.16. The firm had revenue of $585.30 million for the quarter, compared to the consensus estimate of $570.65 million. Charles River Laboratories Intl. had a return on equity of 25.26% and a net margin of 6.38%. The company’s revenue for the quarter was up 24.8% on a year-over-year basis. During the same period last year, the business posted $1.29 EPS. On average, equities research analysts expect that Charles River Laboratories Intl. Inc will post 5.91 earnings per share for the current fiscal year.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: How a Put Option Works

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.